Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GLPG1205 in idiopathic pulmonary fibrosis
2017-004302-18Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GLPG1205 with Placebo (2 arms). Primary endpoint: Change from baseline in FVC (mL) over 26 weeks. Started May 2018; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2017-004302-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004302-18.